Nextech Invest

Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors.

BiotechBoston, US

Alan Huang(Executive Officer)Adam Crystal(Executive Officer)Daniella Beckman(Executive Officer)Douglas Barry(Executive Officer)Aaron Davis(Director)

BoardBarbara Weber(Executive Officer, Director)in

Board seatKanishka Pothula· per SEC Form D

Co-investorsForesite CapitalNSG VenturesThird Rock Ventures

Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.

AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US

Martin Babler(President, Chief Executive Officer and Chairman of the Board)Mark Bradley(Chief Development Officer)Kolbot By(SVP, Head of Technical Operations)Jack Danilkowicz(Chief Commercial Officer)Jörn Drappa(Chief Medical Officer)David M Goldstein(Chief Scientific Officer)

Co-investorsForesite CapitalOrbiMedSamsara BioCapitalSR One Capital ManagementvenBio PartnersWestlake Village BioPartners+1 more

Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.

BiotechHealthtechNew Haven, US

Sean Cassidy(Executive Officer)Manuel Litchman(Executive Officer, Director)

BoardStephen Squinto(Director)inLiam Ratcliffe(Director)Tim Shannon(Director)inKush Parmar(Director)

Co-investors5AM VenturesAccess BiotechnologyCanaan PartnersConnecticut InnovationsRA CapitalSolasta Ventures+1 more

Co-investorsLAVLilly Asia VenturesNew Enterprise Associates (NEA)NSG Ventures

Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.

BiotechMedical DevicesLa Jolla, US

Zachary D. Hornby(Executive Officer, Director)

BoardBenjamin Cravatt, Ph.D.(Director)Kristina Burow(Director)inCarolyn Ng, Ph.D.(Director)Jakob Loven, Ph.D.(Director)Ho Sung Cho, Ph.D.(Director)

Co-investorsARCH Venture PartnersRA Capital

C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease.

BiotechCambridge, US

BoardMarc Cohen(Executive Officer, Director)Jason Fisherman(Executive Officer, Director)Miles Stuchin(Director)Bruce Downey(Director)Bihua Chen(Director)William M. Scalzulli(Director)

Co-investors3E Bioventures CapitalBain Capital Life SciencesRA Capital

Context Therapeutics develops clinical-stage T cell engaging bispecific antibody therapies for the treatment of solid tumors.

BiotechHealthtechPhiladelphia, US

Martin Albert Lehr(Executive Officer, Director)Martin Lehr(Founder)inJennifer Minai-Azary(Executive Officer)Alex Levit(Executive Officer)Linda Beth West(Director)Richard Jay Berman(Director)

Co-investorsTorrey Pines Investment

Cullinan Therapeutics is a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer, with a pipeline that includes CD19- and BCMA-targeted T cell engagers.

BiotechHealthtech

Co-investorsForesite CapitalBiotechnology Value FundOrbiMed

IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers.

BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US

Yujiro Hata(Executive Officer, Director)Paul Stone(Executive Officer)in

BoardTimothy Shannon(Director)inJohn Diekman(Director)inTerry Rosen(Director)Jeffrey Stein(Director)

Co-investors5AM VenturesCanaan Partners

Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.

BiotechDigital HealthMedical DevicesLa Jolla, US

TROY WILSON(Executive Officer, Director)PINGDA REN(Executive Officer)YI LIU(Executive Officer)Troy Wilson(Founder)inHEIDI HENSON(Executive Officer)ANNETTE NORTH(Executive Officer)

Co-investorsARCH Venture PartnersAvoro Capital AdvisorsEcoR1 CapitalForesite CapitalOUP (Osage University Partners)

Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.

BiotechDeep TechHealthtech

Nello Mainolfi(Founder)in

Co-investorsAtlas VentureAvoro Capital AdvisorsBain Capital Life SciencesBessemer Venture PartnersHatteras Venture PartnersMRL Ventures Fund+3 more

ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance.

BiotechHealthtechSouth San Francisco, US

Richard Heyman(Chairman, Founder, Scientific Advisory Board)Charles Sawyers(Founder, Scientific Advisory Board)Scott Lowe(Founder, Scientific Advisory Board)Jacob M. Chacko(Executive Officer, Director)Dominic Piscitelli(Chief Financial Officer)Pratik Multani(Chief Medical Officer)

Co-investorsEcoR1 CapitalNew Enterprise Associates (NEA)Taiho Ventures, LLCThe Column Group

Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.

AI & Machine LearningBiotechDeep TechMedical Devices

Mathai Mammen(CEO, President and Chairman)

Co-investorsARCH Venture PartnersCatalio Capital Management, LPForesite CapitalFrazier Life SciencesGeneral CatalystRA Capital+5 more

BiotechLondon

James Ede-Golightly(Director)Alistair Gray(Director)Craig Tooman(Executive Officer)Dave Lemus(Director)Giles Campion(Executive Officer)Romano Steven(Director)

Co-investorsForesite CapitalMC Healthcare VenturesVivo Capital

Tyra is developing oral dabogratinib, a small-molecule therapy being evaluated in clinical studies for skeletal dysplasia and urologic cancers.

BiotechHealthtechCarlsbad, US

Todd Harris, Ph.D.(Executive Officer, Director)Hiroomi Tada, M.D., Ph.D.(Executive Officer)Daniel Bensen(Executive Officer)Alan Fuhrman(Executive Officer)

BoardRobert More(Director)Nina Kjellson(Director)in

Co-investorsAlta PartnersBioBritCanaan Partners

Zymeworks is a biotechnology company that develops novel therapeutics for patients with difficult-to-treat diseases using its proprietary drug-development platforms and in-house R&D.

BiotechHealthtechVancouver, US

ALI TEHRANI(Executive Officer, Director)GORDON NG(Executive Officer)NEIL KLOMPAS(Executive Officer)SURJIT DIXIT(Executive Officer)DAVID TUCKER(Executive Officer)Paul Moore(Chief Scientific Officer)in

Co-investorsBrace PharmaCTI Life Sciences Fund L.P.Lumira VenturesWUTIF Capital

BiotechBurlingame, US

Mark Rolfe(Executive Officer)Laura Shawver(Executive Officer, Director)Timothy Smith(Executive Officer)

BoardPeter Thompson(Director)Carol Gallagher(Director)

Board seatAlfred Scheidegger· per SEC Form D

Co-investorsAstellas Venture Management LLCNew Enterprise Associates (NEA)5AM VenturesClarus VenturesOrbiMedOsage University Partners+1 more

Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.

AI & Machine LearningBiotechDeep TechPrinceton, US

Ben Cravatt(Scientific Founder)Phil Baran(Scientific Founder)Jin-Quan Yu(Scientific Founder)

BoardJohn Park(Executive Officer)John Clarke(Executive Officer, Director)in

Board seatBenjamin Cravatt· per SEC Form D

Co-investorsARCH Venture PartnersAvoro Capital AdvisorsCardinal PartnersSoftBank Vision FundVersant Ventures

A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications.

BiotechHealthtechAgoura Hills, US

C. Alexander Kamb(Director)Scott Foraker(Executive Officer, Director)Madhavan Balachandran(Director)Michael Gallo(Director)

BoardSrini Akkaraju(Director)inDavid Goeddel(Director)

Co-investorsVida VenturesSamsara BioCapitalThe Column Group

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.

BiotechDigital HealthMedical DevicesVancouver, CA

François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)

Co-investorsAndreessen HorowitzDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude CapitalLumira Ventures+8 more

Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic.

AI & Machine LearningBiotechDeep TechSan Diego, US

Eric A. Murphy(Executive Officer, Director, Promoter)Ryan B. Corcoran(Director, Promoter)

BoardThilo Schroeder(Director)inCarl Gordon(Director)inArjun Goyal(Director)in

Co-investorsCanaan PartnersOrbiMedVida VenturesDigitalis VenturesNVIDIA

Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.

BiotechDeep TechMedical DevicesEindhoven, US

Christian Ottmann(Executive Officer)Josh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)

Co-investorsDroia VenturesMission BiocapitalMRL Ventures FundInkefRA Capital

Co-investorsDCP CapitalApricot Capital

Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.

AI & Machine LearningBiotechDeep TechHealthtechCambridge, US

Michael Gilman(Executive Officer, Director)Mark DeLong(CEO)David Neafus(Executive Officer)Russell C. Petter(Executive Officer)

BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in

Co-investorsCanaan PartnersPfizer VenturesAdvent Life SciencesOUP (Osage University Partners)Pfizer Venture InvestmentsvenBio Partners+1 more

ARS Pharma develops needle-free epinephrine treatments, including neffy, an FDA-approved epinephrine nasal spray for patients and caregivers managing allergic reactions.

BiotechHealthtechMedical DevicesSan Diego, US

Richard Lowenthal(Executive Officer, Director)Pratik Shah(Director)

BoardJonathan Leff(Director)

Co-investorsOrbiMedRA CapitalSR One Capital Management

Atavistik Bio is a clinical-stage biotechnology company developing allosteric small-molecule therapeutics that selectively modulate disease-causing proteins.

BiotechHealthtech

Co-investorsLux CapitalRA CapitalThe Column Group

Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.

BiotechDigital Health

Zaneta Odrowaz(Founder)in

Co-investorsEcoR1 CapitalFrazier Life SciencesIllumina VenturesSanofi VenturesVida VenturesGoldman Sachs

Co-investorsAlta PartnersARCH Venture PartnersDC Investment PartnersLongwood FundPathway to CuresAtlas Venture

Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes.

BiotechHealthtechCambridge, US

Daniel Lynch(Director)Nick Lydon(Director)David Schenkein(Director)Christoph S. Lengauer(Executive Officer)Christine Bellon(Executive Officer)Kyle Kuvalanka(Executive Officer)

Co-investorsF-Prime CapitalForesite CapitalRA Capital

Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.

BiotechSan Mateo, US

Gina Chapman(Executive Officer, Director)Anup Radhakrishnan(Executive Officer)Cassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)

BoardAbraham Bassan(Director)

Co-investorsRed Tree VentureSamsara BioCapitalAlly Bridge GroupJanus Henderson InvestorsPerceptive Xontogeny VentureThird Rock Ventures

Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies.

BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US

Matthew P. Jacobson(Co-founder)Scott R. Lokey(Director)Matthew Jacobson(Director)David J. Earp(President & CEO)Paul Park(Executive Officer)

BoardThilo Schroeder(Director)in

Co-investorsBerkeley CatalystLifeforce CapitalMission Bay CapitalMission BiocapitalPandect BioventuresThe Column Group+1 more

Delphia Therapeutics is a biotechnology company developing cancer medicines based on its activation lethality platform, aiming to create therapies effective on their own while combating resistance to targeted therapies.

BiotechHealthtechCambridge, US

Kevin Marks(Founder)

Co-investorsGV (Google Ventures)Taiho Ventures, LLCAlexandria

Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.

BiotechDeep TechMedical Devices

David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)David LiuAlan Saghetelian

Co-investorsNewpath PartnersCRV (Charles River Ventures)Raptor GroupSamsara BioCapitalCasdin CapitalNovartis Venture Fund

Flare provides software infrastructure and operational support for emergency response teams in government and private sectors, enabling real-time resource management, location tracking, and coordination across multiple agencies to improve response times and effectiveness.

Enterprise SoftwareGovTechSaaSNairobi, KE

Co-investors4Di CapitalInovia CapitalAgent CapitalBase10 PartnersCasdin CapitalInvus+3 more

Flare is a layer 1 blockchain designed for data-intensive decentralized applications, providing enshrined data protocols and infrastructure for developers building with on-chain data.

Crypto & Web3Data & Infrastructure

Co-investorsDigital Currency GroupAgent CapitalBase10 PartnersCasdin CapitalInovia CapitalInvus+3 more

Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.

AI & Machine LearningFuture of WorkHR TechTokyo, JP

Kazuki Kamiya(CEO)Satoru Ichihara(COO)Shinya Hayashi(CSO)Hidefumi Iwaki(CFO)Tomohiro Sasaki(Executive Officer (Product Development))

Co-investorsANOBAKACARTA VENTURES, Inc.Spiral VenturesAgent CapitalBase10 PartnersCasdin Capital+5 more

Flare Therapeutics is a drug discovery company developing small molecule therapies that target transcription factors to restore transcriptional control disrupted by cancer.

BiotechHealthtech

Co-investorsPfizer Venture InvestmentsShangBay Capital LLCAgent Capital

Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.

BiotechHealthtechMedical DevicesNew York, US

Co-investorsKleiner PerkinsNew Enterprise Associates (NEA)Prospect Venture PartnersRho Capital PartnersRho VenturesRiverVest Venture Partners+2 more

Hexagon Bio develops novel payload mechanisms for antibody-drug conjugates (ADCs) aimed at overcoming resistance to current cancer treatments and expanding ADC indications.

BiotechDeep TechHealthtechMenlo Park, US

Colin James Bell Harvey(Director)Brian T. Naughton(Director)Maureen E. Hillenmeyer(Executive Officer, Director)Maureen Hillenmeyer(CEO & Co-Founder)in

BoardAlex Kolich(Director)

Co-investorsB3 HoldingSoftBank Vision FundThe Column Group8VCCasdin CapitalTwo Sigma Ventures

Iconovir is a biotechnology company focused on developing cancer treatments, with a stated mission to cure cancer and restore life to patients.

BiotechHealthtechNew York, US

Sean Algeo(Executive Officer, Promoter)Mark A. McCamish(Executive Officer, Director)David M. Tanen(Executive Officer, Promoter)

BoardDavid Chang(Director, Promoter)Helen Kim(Director)Jakob Loven(Director)in

Co-investorsGV (Google Ventures)Vida VenturesWellington Management

IDRx discovers, develops and delivers medicines and vaccines focused on cancer, HIV, respiratory diseases, and infectious diseases.

BiotechMedical Devices

Tim Clacksonin

Co-investorsAndreessen HorowitzRA Capital

ITM develops radiopharmaceutical diagnostics and therapeutics for precision oncology, using radioisotopes to detect and treat hard-to-treat cancers.

BiotechHealthtechMedical Devices

BiotechCambridge, US

Kim C. Drapkin(Executive Officer)Anna L. Barry(Executive Officer)Richard Murray(Executive Officer, Director)

BoardRobert Tepper(Director)inCary Pfeffer(Director)inRobert Kamen(Director)in

Co-investorsThird Rock Ventures

K36 Therapeutics develops small-molecule inhibitors targeting the histone methyltransferase NSD2 for hematologic and solid tumor cancers.

BiotechHealthtech

Co-investorsAtlas VentureF-Prime Capital

Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases.

BiotechMedical Devices

Co-investorsForesite CapitalAlexandriaLilly Asia VenturesLongwood Fund

BiotechSan Diego, US

Stephen W. Kaldor(Executive Officer, Director, Promoter)Eric Murphy(Executive Officer, Director)

BoardBret Zbar(Director)Carl Gordon(Director)Michael Rome(Director)

Co-investorsForesite CapitalJanus Henderson InvestorsRA CapitalVenrock Healthcare Capital PartnersViking Global Investors

BiotechNew York, US

Norbert Bischofberger, Ph.D.(Executive Officer, Director)Christopher Wilfong(Executive Officer)

BoardRebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)David M. Tanen(Executive Officer, Director, Promoter)Arie S. Belldegrun, M.D.(Director)

Co-investorsEcoR1 CapitalGV (Google Ventures)Vida Ventures

Mariana Oncology, a Novartis company, develops precision radioligand therapies that deliver radioisotopes to diseased cells while limiting effects on healthy tissue.

BiotechHealthtechMedical Devices

Co-investorsAccess BiotechnologyAtlas VentureForbionRA Capital

Day One (part of Servier) is a biopharmaceutical company developing targeted oncology medicines, with a focus on cancers affecting patients of all ages, including pediatric low-grade glioma (pLGG).

BiotechHealthtechCambridge, US

MICHAEL J. KAUFMAN(Executive Officer)DONALD BERGSTROM(Executive Officer)ANNA PROTOPAPAS(Executive Officer, Director)TIMOTHY LOWINGER(Executive Officer)EVA JACK(Executive Officer)SARA NAYEEM(Director)

Co-investorsBain Capital Life SciencesF-Prime CapitalLightstone VenturesNew Enterprise Associates (NEA)Pfizer Venture InvestmentsRho Ventures

Moma Therapeutics is a biotechnology company developing precision medicines by targeting molecular machines that drive human disease.

Biotech

Co-investorsThird Rock VenturesGoldman Sachs

BiotechCambridge, US

Richard Gaynor, M.D.(Executive Officer)Robert Ang, M.D.(Executive Officer)Yasir Al-Wakeel(Executive Officer)Eric Lander(Director)Hugh Dowd(Executive Officer, Director)

BoardCary Pfeffer, M.D.(Director)

Co-investorsSofinnova VenturesClal Biotechnology IndustriesThird Rock Ventures

Nextop IO provides a mobile content delivery network with a client-side library for iOS and Android that routes traffic through optimized proxy servers, reducing latency, improving throughput, and lowering data and battery consumption for mobile applications connecting to backend services.

Data & InfrastructureDeveloper ToolsEnterprise Software

Brien Colwell(Founder/CEO)in

Co-investorsY CombinatorAndreessen HorowitzLightspeed Venture PartnersRA Capital

Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.

BiotechDigital HealthMedical Devices

Co-investorsThe Column GroupVida Ventures

PMV Pharma develops precision oncology therapies that target and structurally correct mutated p53 proteins to restore their tumor-suppressing function.

BiotechHealthtechCranbury, US

David H. Mack, Ph.D.(Founder)inDavid Mack(Executive Officer, Director)Arnold Levine(Director)

BoardPeter Thompson(Director)Steve Winick(Director)Arnold Oronsky(Director)

Co-investorsAvoro Capital AdvisorsOUP (Osage University Partners)RA CapitalOrbiMedOsage University Partners

Co-investorsB Capital GroupB4 CapitalLAVLilly Asia VenturesLYFE CapitalRA Capital

Relay Therapeutics develops small-molecule therapeutics using its Dynamo platform, which combines experimental and computational methods to model protein motion and target proteins considered difficult to drug.

AI & Machine LearningBiotechDeep Tech

Co-investorsEcoR1 CapitalSoftBank Vision FundGeneral Catalyst

Sail Biomedicines develops programmable RNA medicines using circular RNA technology (Endless RNA/eRNA) and targeted nanoparticles for delivery, applying generative AI to design therapies.

AI & Machine LearningBiotechDeep Tech

Co-investorsFlagship PioneeringQuan Capital